Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Carol L. O'brien"'
Autor:
Duncan Wheatley, A. Thompson, Steven Gendreau, Sirwan Hadad, Louise Lim, Lackner, C Zummit, Arnie Purushotham, Nigel J Bundred, Paul N. Mainwaring, Darren Korbie, A Shia, Kelly Mousa, Carol L. O'brien, Robert G. Price, E.J. Macaskill, Peter Schmid, Jennifer J. Hu, Matt Trau, S. Pinder, S-J Sarker, Patrycja Gazinska, Timothy R. Wilson
Publikováno v:
Cancer Research. 79:P2-08
Background: Although preclinical data suggest that combining PI3K inhibitors with endocrine therapy may overcome resistance, results from randomized clinical trials have failed to identify a subgroup of patients that derive a substantial benefit. Thi
Autor:
Charles Zammit, Nigel J Bundred, Carol L. O'brien, Louise Lim, Arnie Purushotham, A Shia, A. Thompson, Jun Yu, Lukas C. Amler, Peter J. Parker, Lackner, Sarah E Pinder, Luciana Molinero, Robert G. Price, Jennifer J. Hu, Mika K. Derynck, Timothy R. Wilson, Jane Macaskill, Steven Gendreau, Heidi Savage, Peter Schmid, Duncan Wheatley
Publikováno v:
Cancer Research. 76:P5-13
Background: The OPPORTUNE Study randomized postmenopausal patients (pts) to receive 2-week preoperative treatment with anastrozole (ANA) plus pictilisib ("ANA+PIC" arm) or ANA alone. Patients had newly diagnosed, operable, ER+, HER2- invasive breast
Autor:
Wei Zhou, Heather M. Moore, Mark R. Lackner, Heidi Savage, Ciara Metcalfe, Timothy R. Wilson, Carol L. O'brien
Publikováno v:
Cancer Research. 77:1780-1780
The phosphoinositol-3-kinase (PI3K) signaling pathway is one of the most frequently activated pathways in cancer, and controls critical cellular processes such as proliferation, transcription and survival. Taselisib (GDC0032) is an orally bioavailabl
Autor:
Carol L. O'Brien
Publikováno v:
New Directions for Philanthropic Fundraising. 1998:9-22
Campaigns are not primarily about raising money. They are catalysts for organizational change and transformation, providing opportunities for sustained focus on vision and values.
Autor:
Heidi Savage, Rajesh Patel, Joyce A. O'Shaughnessy, Timothy R. Wilson, Erica B. Schleifman, Ling Huw, Ling Fu, Yuanyuan Xiao, Carol L. O'brien, Rachel Tam, Jill M. Spoerke, Mark R. Lackner, Teiko Sumiyoshi, Hartmut Koeppen
Publikováno v:
Cancer Research. 74:LB-179
Current clinical practice stratifies patients for treatment and enrollment in clinical breast cancer studies based on ER, PR and HER2 status. Emerging data suggest that these three biomarkers do not fully capture the heterogeneity that exists within
Autor:
C Criscitello, Sherene Loi, Ling-Yuh Huw, Heidi Savage, M.J. Piccart, Lackner, Christos Sotiriou, Roberto Salgado, I Laios, Carol L. O'brien, L Pugliano, Stefan Michiels, Debora Fumagalli, Timothy R. Wilson
Publikováno v:
Cancer Research. 73:P6-05
Introduction. Understanding the genetic landscape of estrogen receptor positive breast caner is critical for defining clinically actionable alleles that may be targeted using next generation biologics. PIK3CA mutations have previously been reported t
Autor:
Jill M. Spoerke, Heidi Savage, Jeffrey Wallin, Lori Friedman, Lackner, Carol L. O'brien, Timothy R. Wilson, Ling-Yuh Huw
Publikováno v:
Cancer Research. 73:P6-05
Introduction The PI3-Kinase pathway is one of the most commonly mutated pathways in cancer and plays a major role in cell proliferation and survival. Mutations in PIK3CA, the gene encoding the p110 subunit of PI3K, are among the most common alteratio
Autor:
Ling Huw, Jill M. Spoerke, Marcin Kowanetz, Timothy R. Wilson, Yuanyuan Xiao, Carol L. O'brien, Priti S. Hegde, Mark R. Lackner
Publikováno v:
Cancer Research. 73:2382-2382
Breast cancer is a heterogeneous disease that is commonly divided into 3 specific subtypes. Hormone receptor positive breast cancers that express either the estrogen or progesterone receptors are commonly treated with anti-estrogen therapies and have
Autor:
Jill M. Spoerke, Carol L. O'brien, Scott Sproul, Garret Hampton, Peter M. Haverty, Mark R. Lackner
Publikováno v:
Cancer Research. 72:5609-5609
GDC-0941 is a class I PI3 kinase inhibitor of all 4 isoforms currently in phase II clinical trials in multiple indications, including ER+ breast cancer. The PI3 kinase pathway plays an important role in proliferation and survival and is known to be o